Access to medicines that people need should be universally equitable and sustainable. The medicines should be safe, effective and of good quality. They should be prescribed by relevant authority and used rationally.
The majority of low and middle-income countries now use essential medicines lists in selecting their medicines. This may be further developed with the introduction of generic competition, which helps to maintain low prices. Schemes such as bulk purchasing, careful price comparison, compulsory licensing and differential pricing schemes, may all help countries obtain better purchasing prices for medicines, and also ensure sustainability of long-term pharmaco-healthcare provision.